Drug Trial Radar · NCT06278038
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Feb 22, 2024
Primary completion
Nov 10, 2024
Study completion Nov 19, 2024
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.
Conditions
- Major Depression Disorder
Interventions
Toludesvenlafaxine hydrochloride sustained-release tabletsDrug
80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
Venlafaxine hydrochloride sustained-release tabletsDrug
75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Snaith-Hamilton Pleasure Scale (SHAPS) Total ScoreTime frame: Baseline and the end of week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.